Solid Biosciences (NASDAQ:SLDB) Share Price Breaks Above 50 Day Moving Average – Should You Sell?

Solid Biosciences Inc. (NASDAQ:SLDB)’s share price passed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $7.33 and traded as high as $7.86. Solid Biosciences shares last traded at $7.60, with a volume of 1,957,909 shares changing hands.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SLDB. Royal Bank Of Canada assumed coverage on shares of Solid Biosciences in a research note on Wednesday, September 16th. They set an “outperform” rating and a $18.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, October 15th. Cantor Fitzgerald upped their target price on shares of Solid Biosciences from $16.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. UBS Group assumed coverage on shares of Solid Biosciences in a research note on Wednesday, October 14th. They set a “buy” rating and a $20.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating on shares of Solid Biosciences in a report on Tuesday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.00.

Solid Biosciences Price Performance

The company has a 50-day simple moving average of $7.33 and a 200-day simple moving average of $7.67. The stock has a market cap of $848.24 million, a PE ratio of -4.25 and a beta of 2.65.

Solid Biosciences (NASDAQ:SLDB) last released its earnings results on Wednesday, November 4th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.05. On average, equities analysts expect that Solid Biosciences Inc. will post -1.60 EPS for the current fiscal year.

Institutional Trading of Solid Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new position in Solid Biosciences in the second quarter valued at about $2,429,000. Dimensional Fund Advisors LP lifted its position in shares of Solid Biosciences by 40.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 956,135 shares of the company’s stock valued at $6,877,000 after acquiring an additional 277,051 shares during the period. Redmile Group LLC boosted its stake in shares of Solid Biosciences by 8.1% during the 1st quarter. Redmile Group LLC now owns 2,011,895 shares of the company’s stock worth $14,486,000 after acquiring an additional 151,353 shares in the last quarter. Stempoint Capital LP purchased a new stake in shares of Solid Biosciences during the 1st quarter worth approximately $1,407,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of Solid Biosciences during the 1st quarter worth approximately $28,877,000. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences is a biotechnology company developing genetic medicines for Duchenne muscular dystrophy and other serious neuromuscular and cardiac diseases. The company’s research focuses on gene-transfer approaches intended to address underlying causes of these conditions. Its lead program, SGT-003, is an investigational gene therapy being developed for Duchenne muscular dystrophy. Solid Biosciences also has research programs targeting other rare diseases. These programs are in development, and its therapies have not been established as approved treatments.